NASDAQ: XTLBXtl Biopharmaceuticals Ltd Stock
$2.44-0.03 (-1.21%)
Updated Apr 18, 2024
XTLB Price
$2.44
Fair Value Price
$0.82
Market Cap
$13.30M
52 Week Low
$0.75
52 Week High
$4.99
P/E
-12.2x
P/B
3.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$1.35M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$901k
Beta
0.63
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
XTLB Overview
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XTLB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XTLB ($2.44) is overvalued by 197.06% relative to our estimate of its Fair Value price of $0.82 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
XTLB ($2.44) is not significantly undervalued (197.06%) relative to our estimate of its Fair Value price of $0.82 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
XTLB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XTLB due diligence checks available for Premium users.
Be the first to know about important XTLB news, forecast changes, insider trades & much more!
XTLB News
Valuation
XTLB fair value
Fair Value of XTLB stock based on Discounted Cash Flow (DCF)
Price
$2.44
Fair Value
$0.82
Overvalued by
197.06%
XTLB ($2.44) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XTLB ($2.44) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XTLB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XTLB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-12.2x
Industry
15.68x
Market
41.33x
XTLB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.32x
Industry
5.76x
XTLB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XTLB's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.3M
Profit Margin
0%
XTLB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.2M
Liabilities
$187.0k
Debt to equity
0.05
XTLB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XTLB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$901.0k
Investing
$36.0k
Financing
$0.0
XTLB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XTLB vs Biotech Stocks
Xtl Biopharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.